Cargando…

Clinical Analysis and Optimization of Postremission Therapy for Acute Myeloid Leukemia Patients with Minimal Residual Disease as Determined by Flow Cytometry.

BACKGROUND: Although several prognostic indicators of de novo acute myeloid leukemia (AML) patients have been identified, the clinical significance of minimal residual disease (MRD) needs to be evaluated further in Japanese adult patients. METHODS: Using three color flow cytometry, we identified leu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Daichi, Maruoka, Hayato, Takahashi, Takayuki
Formato:	Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2010
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033143/ https://www.ncbi.nlm.nih.gov/pubmed/21415971 http://dx.doi.org/10.4084/MJHID.2010.020

Ejemplares similares

Postremission sequential monitoring of minimal residual disease by WT1 Q‐PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk‐adapted therapy in acute myeloid leukemia patients
por: Malagola, Michele, et al.
Publicado: (2015)

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia
por: Vial, Jean Philippe, et al.
Publicado: (2021)

Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia
por: Chen, Man, et al.
Publicado: (2023)

T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia
por: Xue, Lei, et al.
Publicado: (2019)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
por: Röhnert, Maximilian A., et al.
Publicado: (2022)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia
por: Norkin, Maxim, et al.
Publicado: (2017)

Flow Cytometry and Polymerase Chain Reaction-Based Analyses of Minimal Residual Disease in Chronic Lymphocytic Leukemia
por: Uhrmacher, Sabrina, et al.
Publicado: (2010)

Minimal residual disease detection by multicolor flow cytometry in cryopreserved ovarian tissue from leukemia patients
por: Zver, Tristan, et al.
Publicado: (2022)

P55. Dendritic cell vaccination for postremission therapy in AML
por: Lichtenegger, FS, et al.
Publicado: (2014)

Acute monocytic leukemia diagnosed by flow cytometry includes acute myeloid leukemias with weakly or faintly positive non-specific esterase staining
por: Zushi, Yuriko, et al.
Publicado: (2018)

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
por: Bar, Merav, et al.
Publicado: (2014)

Re-Emergence of Minimal Residual Disease Detected by Flow Cytometry Predicts an Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia
por: Wang, Yu, et al.
Publicado: (2021)

Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia
por: Liu, Fu-Jia, et al.
Publicado: (2021)

Artificial Intelligence Enhances Diagnostic Flow Cytometry Workflow in the Detection of Minimal Residual Disease of Chronic Lymphocytic Leukemia
por: Salama, Mohamed E., et al.
Publicado: (2022)

Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
por: Nematollahi, Pardis, et al.
Publicado: (2020)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
por: Vonk, Christian M., et al.
Publicado: (2021)

Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going
por: Dix, Caroline, et al.
Publicado: (2020)

Identifying Leukemia-associated Immunophenotypes in Acute Myeloid Leukemia Patients Using Multiparameter Flow Cytometry
por: Rasheed, Hadeer Mohamed, et al.
Publicado: (2021)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
por: Tettero, Jesse M., et al.
Publicado: (2021)

Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome
por: Ko, Bor-Sheng, et al.
Publicado: (2018)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
por: Foureau, David M., et al.
Publicado: (2023)

Combined usage of Wilms' tumor gene quantitative analysis and multiparameter flow cytometry for minimal residual disease monitoring of acute myeloid leukemia patients after allogeneic hematopoietic stem cells transplantation
por: Hao, Yingchan, et al.
Publicado: (2018)

Correction Notice: Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Publicado: (2022)

Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry
por: Gupta, Monali, et al.
Publicado: (2020)

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
por: Simoes, Catia, et al.
Publicado: (2022)

Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies
por: Buldini, Barbara, et al.
Publicado: (2019)

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker
por: Alizad Ghandforoush, Nasrin, et al.
Publicado: (2016)

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
por: Mosna, Federico, et al.
Publicado: (2017)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection
por: Srinivasan Rajsri, Kritika, et al.
Publicado: (2023)

Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction
por: Cheng, Suk Hang, et al.
Publicado: (2013)

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
por: Kastritis, Efstathios, et al.
Publicado: (2018)

Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry‐based leukemic cell enrichment followed by mutational profiling
por: Daga, Shruti, et al.
Publicado: (2020)

Automated Deep Learning-Based Diagnosis and Molecular Characterization of Acute Myeloid Leukemia using Flow Cytometry
por: Lewis, Joshua E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vtkvl0k0ob6uaq9v3bn07ehvga